Nadeem Kamran, MD
Internal Medicine · la Porte, INNPI 1275696171
Payments from drug & device makers
Across 178 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$609
- Bayer$332
- Lilly USA, LLC$271
- Novo Nordisk$247
- Novartis$232
- Pfizer$202
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,228100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $609 |
| Bayer | 28 | $332 |
| Lilly USA, LLC | 16 | $271 |
| Novo Nordisk | 14 | $247 |
| Novartis | 14 | $232 |
| Pfizer | 9 | $202 |
| Otsuka America Pharmaceutical, Inc. | 9 | $175 |
| AstraZeneca | 7 | $125 |
| Mylan Specialty L.p. | 4 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $88 |
| GSK | 5 | $80 |
| Vanda Pharmaceuticals Inc. | 2 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| Exact Sciences | 4 | $69 |
| Johnson & Johnson | 3 | $61 |
| Xeris Pharmaceuticals, Inc. | 2 | $49 |
| Merck | 3 | $46 |
| Abbott | 2 | $44 |
| EDW Pharma, Inc. | 1 | $44 |
| Astellas Pharma US Inc | 2 | $40 |
| Viatris Specialty LLC | 2 | $38 |
| Dexcom, Inc. | 2 | $36 |
| Aimmune Therapeutics, Inc. | 1 | $34 |
| Scpharmaceuticals Inc. | 1 | $29 |
| Lundbeck LLC | 1 | $22 |
| Amgen | 1 | $19 |
| Medtronic | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Almatica Pharma LLC | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$3,228 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,138 | $329,777 |
| MounjaroTirzepatide | 128 | $160,992 |
| RybelsusSemaglutide | 81 | $132,705 |
| CreonLipase/Protease/Amylase | 87 | $79,162 |
| TrulicityDulaglutide | 66 | $65,185 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $61,590 |
| OzempicSemaglutide | 45 | $56,030 |
| XareltoRivaroxaban | 102 | $47,004 |
| XifaxanRifaximin | 31 | $45,902 |
| EntrestoSacubitril/Valsartan | 93 | $45,222 |
| TradjentaLinagliptin | 139 | $43,580 |
| JardianceEmpagliflozin | 56 | $31,124 |
| LinzessLinaclotide | 53 | $30,026 |
| MyrbetriqMirabegron | 76 | $26,354 |
| KerendiaFinerenone | 16 | $23,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $202 | $329,7771,138 claims |
| Lilly USA, LLCMounjaro, Trulicity | $271 | $226,177194 claims |
| Novo NordiskRybelsus, Ozempic | $247 | $188,735126 claims |
| AbbVieCreon, Linzess | $609 | $109,189140 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $80 | $72,47486 claims |
| Johnson & JohnsonXarelto | $61 | $47,004102 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $12 | $45,90231 claims |
| NovartisEntresto | $232 | $45,22293 claims |
| Astellas Pharma US IncMyrbetriq | $40 | $26,35476 claims |
| BayerKerendia | $332 | $23,07916 claims |
| AstraZenecaFarxiga | $125 | $17,18754 claims |
| Almatica Pharma LLCSertraline Hcl | $14 | $9,0161,239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in la Porte
- Joseph Arulandula Porte$251K
- Vinay Tumulurila Porte$23K
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.